NASDAQ:PSTV Plus Therapeutics (PSTV) Stock Price, News & Analysis $1.30 0.00 (0.00%) (As of 10/4/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends About Plus Therapeutics Stock (NASDAQ:PSTV) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Plus Therapeutics alerts:Sign Up Key Stats Today's Range$1.28▼$1.3450-Day Range$1.22▼$1.8552-Week Range$0.97▼$2.78Volume34,320 shsAverage Volume59,602 shsMarket Capitalization$7.42 millionP/E RatioN/ADividend YieldN/APrice Target$14.00Consensus RatingBuy Company OverviewPlus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.Read More… Next opportunity for crypto millions (Ad)October isn't just another month in crypto. It's the launchpad for what could be the most explosive bull run in history. And I've found the rocket fuel… One coin is quietly positioning itself to outperform the entire market. The signs are everywhere…Go here to discover the coin that could define this historic bull run with gains kicking off this mo Plus Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks56th Percentile Overall ScorePSTV MarketRank™: Plus Therapeutics scored higher than 56% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingPlus Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoveragePlus Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Plus Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Plus Therapeutics are expected to grow in the coming year, from ($2.22) to ($1.56) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Plus Therapeutics is -0.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Plus Therapeutics is -0.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Plus Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.92% of the float of Plus Therapeutics has been sold short.Short Interest Ratio / Days to CoverPlus Therapeutics has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Plus Therapeutics has recently increased by 51.00%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPlus Therapeutics does not currently pay a dividend.Dividend GrowthPlus Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.92% of the float of Plus Therapeutics has been sold short.Short Interest Ratio / Days to CoverPlus Therapeutics has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Plus Therapeutics has recently increased by 51.00%, indicating that investor sentiment is decreasing significantly. News and Social Media2.2 / 5News Sentiment0.04 News SentimentPlus Therapeutics has a news sentiment score of 0.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Plus Therapeutics this week, compared to 1 article on an average week.Search Interest2 people have searched for PSTV on MarketBeat in the last 30 days. Company Ownership1.7 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Plus Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $27,744.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 2.32% of the stock of Plus Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 3.28% of the stock of Plus Therapeutics is held by institutions.Read more about Plus Therapeutics' insider trading history. Receive PSTV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Plus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address PSTV Stock News HeadlinesPlus Therapeutics reports progress in brain cancer trialOctober 3 at 5:57 PM | uk.investing.comPlus Therapeutics Reports ReSPECT-GBM Clinical Trial Update at the 2024 Congress of Neurological Surgeons Annual MeetingOctober 1, 2024 | globenewswire.comNext opportunity for crypto millions"Uptober" is here, and it's not just a clever name. Historically, October ignites crypto's most explosive gains. This year could be off the charts. Don't let this opportunity pass you by. In crypto, timing is everything. October 6, 2024 | Crypto 101 Media (Ad)Dow Tumbles Over 200 Points; Carnival Posts Upbeat EarningsSeptember 30, 2024 | benzinga.comPlus Therapeutics (NASDAQ:PSTV) Stock, Short Interest ReportSeptember 29, 2024 | benzinga.comPlus Therapeutics, Inc. (NASDAQ:PSTV) Short Interest UpdateSeptember 27, 2024 | americanbankingnews.comPlus Therapeutics Showcases New Interim ReSPECT-GBM Phase 2 Trial Data at the 2024 Congress of Neurological Surgeons Annual MeetingSeptember 18, 2024 | globenewswire.comPlus Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 4, 2024 | globenewswire.comSee More Headlines PSTV Stock Analysis - Frequently Asked Questions How have PSTV shares performed this year? Plus Therapeutics' stock was trading at $1.7501 at the start of the year. Since then, PSTV stock has decreased by 25.7% and is now trading at $1.30. View the best growth stocks for 2024 here. How were Plus Therapeutics' earnings last quarter? Plus Therapeutics, Inc. (NASDAQ:PSTV) issued its quarterly earnings data on Wednesday, August, 14th. The company reported ($0.71) earnings per share (EPS) for the quarter. The business earned $1.28 million during the quarter. Plus Therapeutics had a negative net margin of 240.15% and a negative trailing twelve-month return on equity of 805.57%. When did Plus Therapeutics' stock split? Plus Therapeutics shares reverse split on Monday, May 1st 2023. The 1-15 reverse split was announced on Monday, May 1st 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, May 1st 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. How do I buy shares of Plus Therapeutics? Shares of PSTV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Plus Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Plus Therapeutics investors own include Advanced Micro Devices (AMD), Trevena (TRVN), Chimerix (CMRX), Genocea Biosciences (GNCA), Sorrento Therapeutics (SRNE) and Akero Therapeutics (AKRO). Company Calendar Last Earnings8/14/2024Today10/05/2024Next Earnings (Estimated)10/29/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryMedical Equipment Current SymbolNASDAQ:PSTV CUSIPN/A CIK1095981 Webwww.plustherapeutics.com Phone737-255-7194Fax858-450-4335Employees20Year Founded1996Price Target and Rating Average Stock Price Target$14.00 High Stock Price Target$20.00 Low Stock Price Target$8.00 Potential Upside/Downside+976.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($3.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-13,320,000.00 Net Margins-240.15% Pretax Margin-240.15% Return on Equity-805.57% Return on Assets-127.52% Debt Debt-to-Equity RatioN/A Current Ratio0.50 Quick Ratio0.50 Sales & Book Value Annual Sales$4.91 million Price / Sales1.51 Cash FlowN/A Price / Cash FlowN/A Book Value($0.30) per share Price / Book-4.33Miscellaneous Outstanding Shares5,704,000Free Float5,572,000Market Cap$7.42 million OptionableNot Optionable Beta0.67 Social Links 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report This page (NASDAQ:PSTV) was last updated on 10/6/2024 by MarketBeat.com Staff From Our Partners⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredGolden Equation: Volatility = OpportunityWhen the market swings wildly, most investors panic… But it doesn't have to be this way. You see, when t...Prosper Trading Academy | SponsoredAI expert reveals new Nvidia predictionEveryone’s talking about AI right now, but I’ve been talking about it for years. And now I’ve just released...Brownstone Research | SponsoredNext opportunity for crypto millionsAll the Pieces Falling into Place for Crypto… Unlock the Potential of the 2024 Crypto Bull Run!Crypto 101 Media | SponsoredWho are Nvidia’s New Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredWar on Elon Escalates… Elon Musk, the guy slated to become the world’s first trillionaire by 2027, has publicly called for the adopti...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Plus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Plus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.